PS
MRNS

Principal Securities’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Principal Securities’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-457
Closed -$804 – 3669
2024
Q3 		$804 Hold
457
– – ﹤0.01% 3183
2024
Q2 		$535 Buy
+457
New +$1.14K ﹤0.01% 3189

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Securities's MRNS Position: Q4 2024 in Review

Principal Securities sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 457 shares — an estimated $804 sold.

Principal Securities first reported a position in MRNS in Q2 2024 and held it in 2 quarters. The position peaked at $804 in Q3 2024. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Principal Securities reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Principal Securities sold 457 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $804.
  • Principal Securities first reported a position in Marinus Pharmaceuticals, Inc in Q2 2024 and held it in 2 quarters.
  • Principal Securities's Marinus Pharmaceuticals, Inc position peaked at $804 in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Principal Securities's 13F filing for Q4 2024, filed 30 Jan 2025.